. 2020 Oct 22;25(42):1900576. doi: 10.2807/1560-7917.ES.2020.25.42.1900576

Table 3. Determinants, according to logistic regression analysis, of resistance to penicillin (MIC > 1 mg/L), cefixime (MIC > 0.125 mg/L), azithromycin (ECOFF > 1 mg/L) and ciprofloxacin (MIC > 0.06 mg/L) in Neisseria gonorrhoeae isolates from primary healthcare units and Drassanes-Vall d’Hebron sexually transmitted infection unit, Barcelona, Spain, 2013–2017 (n = 2,036).

Variable	Number of resistant isolates	Total isolates tested	%	Univariable		Multivariable		Number of resistant isolates	Total isolates tested	%	Univariable		Multivariable
Variable	Number of resistant isolates	Total isolates tested	%	OR (95%CI)	p value	OR (95%CI)	p value	Number of resistant isolates	Total isolates tested	%	OR (95%CI)	p value	OR (95%CI)	p value
Antibiotic	Penicillin							Cefimixime
Year
2013	92	327	28.1	1 (ref)	0.0000	1 (ref)	0.0000	27	327	8.3	1 (ref)	0.0064	1 (ref)	0.0073
2014	88	339	26.0	0.93 (0.66–1.33)		0.97 (0.68–1.38)		18	339	5.3	0.63 (0.33–1.20)		0.67 (0.35–1.29)
2015	73	339	21.5	0.73 (0.51–1.05)		0.70 (0.49–1.01)		5	339	1.5	0.19 (0.07–0.50)		0.20 (0.07–0.52)
2016	76	408	18.6	0.61 (0.42–0.86)		0.59 (0.42–0.85)		23	408	5.6	0.60 (0.32–1.12)		0.61 (0.32–1.16)
2017	70	572	12.2	0.34 (0.24–0.49)		0.33 (0.23–0.47)		25	572	4.4	0.43 (0.23–0.80)		0.43 (0.23–0.80)
Total	399	1,985	NA	NA	NA	NA	NA	98	1,985	NA	NA	NA	NA	NA
Sex
Male	388	1,895	20.5	1 (ref)	0.1786	1 (ref)	0.1067	88	1,896	4.6	1 (ref)	0.0074	1 (ref)	0.0303
Female	11	88	12.5	0.55 (0.23–1.31)	0.1786	0.49 (0.20–1.17)	0.1067	10	87	11.5	3.36 (1.38–8.16)	0.0074	2.72 (1.10–6.72)	0.0303
Total	399	1,983^a	NA	NA	NA	NA	NA	98	1,983^a	NA	NA	NA	NA	NA
Clinical setting
DVHSTI (n = 1,340^b)	242	1,303	18.6	1 (ref)	0.0041	1 (ref)	0.0006	46	1,303	3.5	1 (ref)	0.0064	1 (ref)	0.0050
PH (n = 579^b)	138	566	24.4	1.41 (1.12–1.79)	0.0041	1.53 (1.20–1.95)	0.0006	36	565	6.4	1.86 (1.19–2.92)	0.0064	1.91 (1.22–3.01)	0.0050
Total	380^c	1,869^c	NA	NA	NA	NA	NA	82^c	1,868^c	NA	NA	NA	NA	NA
Antibiotic	Azithromycin							Ciprofloxacin
Year
2013	11	322	3.4	1 (ref)	0.5295	1 (ref)	0.5939	162	325	49.8	1 (ref)	0.0771	1 (ref)	0.0846
2014	5	340	1.5	0.42 (0.15–1.23)		0.45 (0.15–1.30)		167	340	49.1	1.01 (0.74–1.39)		1.06 (0.77–1.45)
2015	7	339	2.1	0.60 (0.23–1.57)		0.60 (0.23–1.57)		192	338	56.8	1.45 (1.06–1.99)		1.44 (1.05–1.98)
2016	12	408	2.9	0.81 (0.34–1.89)		0.81 (0.35–1.90)		213	407	52.3	1.11 (0.82–1.50)		1.11 (0.82–1.50)
2017	17	572	3	0.87 (0.40–1.88)		0.85 (0.39–1.84)		284	576	49.3	1.002 (0.758–1.325)		0.98 (0.74–1.30)
Total	52	1,981	NA	NA	NA	NA	NA	1,018	1,986	51.3	NA	NA	NA	NA
Sex
Male	50	1,891	2.6	1 (ref)	0.5410	1 (ref)	0.6184	965	1,896	50.9	1 (ref)	0.9312	1 (ref)	0.9832
Female	2	88	2.2	1.57 (0.37–6.65)	0.5410	1.45 (0.34–6.22)	0.6184	53	88	60.2	0.98 (0.55–1.73)	0.9312	0.99 (0.56–1.77)	0.9832
Total	52	1,979^a	NA	NA		NA	NA	1,018	1,984^a	NA	NA	NA	NA	NA
Clinical setting
DVHSTI (n = 1,340^b)	28	1,302	2.2	1 (ref)	0.0207	1	0.0272	612	1,303	47.0	1	0.0000	1 (ref)	0.0000
PH (n = 579^b)	23	563	4.1	1.94 (1.11–3.39)	0.0207	1.89 (1.07–3.31)	0.0272	332	567	58.6	1.63 (1.34–1.99)	0.0000	1.63 (1.33–1.99)	0.0000
Total	51^c	1,865^c	NA	NA	NA	NA	NA	944^c	1,870^c	NA	NA	NA	NA	NA

CI: confidence interval; DVHSTI: Drassanes-Vall d’Hebron sexually transmitted infection unit; ECOFF: epidemiological cut-off value; MIC: minimum inhibitory concentration; NA: not applicable; OR: odds ratio; PH: primary healthcare unit.

^a There are two patients for whom sex is not known.

^b Number of isolates received by the setting.

^c Isolates from Vall d’Hebron University Hospital are not included in the statistical analyses relating to clinical setting.